Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Alnylam has received investment from 3 venture capital firms.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam has received investment from Anthos Capital, RA Capital Management, Roche Venture Fund. These venture capital firms and investors provide both capital and strategic support.
Alnylam was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam operates in the Biotech sector. Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined...
